Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus

Belimumab (Benlysta) inhibits the B-lymphocyte simulator, and thus inhibits B cells, which are believed to play an important role in the pathophysiology of systematic lupus erythematosus (SLE). It is indicated, in addition to standard therapy, for reducing disease activity in adult patients with act...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) CADTH 2020, June 2020
Edition:	Final (with redactions)
Series:	CADTH common drug review
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK564629
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa